Abstract
Summary and conclusions
The toxic effects of 4-aminopyrazolo-(3,4-d)-pyrimidine (4-APP) have been studied in mice, rats, cats, and dogs. The agent was found to produce a fatty change in liver which was associated neither with necrosis nor with inflammation. Hepatic insufficiency was evidenced by hyperbilirubinemia, increases in one-stage prothrombin time and decreases in plasma fibrinogen. In rats fat nephrosis and depletion of hematopoietic elements in bone marrow were also seen. Hepatic insufficiency should be anticipated as a possible hazard in clinical trials with 4-APP.
Get full access to this article
View all access options for this article.